Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers

The high frequency of homologous recombination deficiency (HRD) is the main rationale of testing platinum-based chemotherapy in triple-negative breast cancer (TNBC), however, the existing methods to identify HRD are controversial and there is a medical need for predictive biomarkers. We assess the i...

Descripción completa

Detalles Bibliográficos
Autores principales: ter Brugge, Petra, Moser, Sarah C., Bièche, Ivan, Kristel, Petra, Ibadioune, Sabrina, Eeckhoutte, Alexandre, de Bruijn, Roebi, van der Burg, Eline, Lutz, Catrin, Annunziato, Stefano, de Ruiter, Julian, Masliah Planchon, Julien, Vacher, Sophie, Courtois, Laura, El-Botty, Rania, Dahmani, Ahmed, Montaudon, Elodie, Morisset, Ludivine, Sourd, Laura, Huguet, Léa, Derrien, Heloise, Nemati, Fariba, Chateau-Joubert, Sophie, Larcher, Thibaut, Salomon, Anne, Decaudin, Didier, Reyal, Fabien, Coussy, Florence, Popova, Tatiana, Wesseling, Jelle, Stern, Marc-Henri, Jonkers, Jos, Marangoni, Elisabetta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082194/
https://www.ncbi.nlm.nih.gov/pubmed/37029129
http://dx.doi.org/10.1038/s41467-023-37537-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082194/
https://www.ncbi.nlm.nih.gov/pubmed/37029129
http://dx.doi.org/10.1038/s41467-023-37537-2

Ejemplares similares